tirzepatide and thyroid cancer Possible pro-oncogenic effect of (TRZD) on the GLP-1 Medications and Thyroid Cancer

This keeps you clear of sensitive areas

Am J Clin Nutr

Sickle cell disease patients in U.S

Before tirzepatide, Lilly was developing its own GLP-1-only agonists (e.g., dulaglutide) and amylin analogs, and it launched baricitinib/therapies in inflammation

In contrast, previous studies with mouse models of oncogenedriven cancers have shown that oncogenederived adenomas did not progress to cancers and were instead diverted to indolent benign oncocytic tumors, indicating the essentiality of autophagy for the progression of benign tumors to a more malignant state (see ref ( Kras G12D or Braf V600E , the conditional KO of ATG5 or ATG7 accelerated tumor initiation as mentioned above, which were, however, diverted to benign oncocytoma ( Atg7 KO/KO mice mentioned above ( It should be noted here that, clinically, oncocytomas are usually benign in many tissues, with the thyroid being an exception ( Braf thyrV600E ,Atg5 thyrKO/KO and Braf thyrV600E ,Mieap KO/KO mice were not oncocytic